Keywords: Pfizer, Xeljanz, Tofacitinib, Rheumatoid arthritis, US, FDA

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

Article | 07 November 2012

Print This

Having in the summer put back its “action date” due to a request for additional analysis of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in